PAVM News and Press, PAVmed Inc. From 05/12/22

PAVmed Inc. (PAVM) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Adrian Miller - VP, IR Lishan Aklog - Chairman and CEO Dennis McGrath - President and CFO Conference Call Participants Ross Osborn - Cantor Fitzgerald Jeremy Pearlman - Maxim Group Ed Woo - Ascend...

PAVmed press release (NASDAQ:PAVM): Q1 Non-GAAP EPS of -$0.14 beats by $0.05. Revenue of $0.2M misses by $0.15M. For further details see: PAVmed Non-GAAP EPS of -$0.14 beats by $0.05, revenue of $0.2M misses by $0.15M

Conference call to be held today at 4:30 PM EDT PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health...

AAIC, ACB, ACHV, AFRM, AGRO, AGRX, APDN, APTX, AQN, AVPT, AXU, BANX, BBI, BEAT, BIOL, BLBD, BLND, BOXL, BSQR, CBAY, CDXC, CLLS, CLVR, CODX, COMP, CORZ, CRMD, CTIC, CURI, CWCO, DARE, DUOL, EDR, ETON, EYEN, FIGS, GPL, GWH, HLI, HTGM, IBIO, IDN, OTCQB:IGXT, IMMR, INDI, INTZ, INUV, JOBY, KMPH, LC...

Conference call to be held today at 4:30 PM EDT Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”, the “Company”), a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq...

Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...

The stock market crash continues this week, with shares of companies retreating on Monday morning. Investors are taking bearish bets that inflation may not have peaked. Meanwhile, supply chain issues remain a factor, and headwinds persist from last week’s Fed meeting. Whether it ...

Lucid’s first commercial payer agreement provides in-network access and payment for its EsoGuard ® DNA test to over 8 million covered lives Lucid Diagnostics Inc. (Nasdaq: LUCD ) (“Lucid”, the “Company”) a commercial-st...

Lucid Diagnostics Selects Veeva Vault CDMS for EsoGuard® Study PR Newswire Vault CDMS to manage clinical data for trial involving Barrett's esophagus and esophageal adenocarcinoma patients PLEASANTON, Calif. , May 4, 2022 /PRNewswire/ -...

Gainers: Vivakor (VIVK) +91%. Digital World Acquisition (DWAC) +33%. Studio City International Holdings (MSC) +31%. Tempest Therapeutics (TPST) +30%. PAVmed  (PAVM) +17%. AppTech Payments (APCX) +16%. Priority Technology Holdings (PRTH) +14%. Fusion Pharmaceuticals (FUSN) +14%. Alkermes ...